← Back to Search

Histone Deacetylase Inhibitor

HBI-8000 + Pembrolizumab for Non-Small Cell Lung Cancer (HBI-8000 Trial)

Phase 2
Waitlist Available
Research Sponsored by HUYABIO International, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 38 months
Awards & highlights

HBI-8000 Trial Summary

This trial is testing a new cancer drug, HBI-8000, to see if it can help people with advanced lung cancer who have a protein called PD-L1.

Eligible Conditions
  • Non-Small Cell Lung Cancer

HBI-8000 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~38 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 38 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate (ORR)
Secondary outcome measures
Disease Control Rate (DCR)
Duration of response (DoR)
Progression-Free Survival (PFS)
+1 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

HBI-8000 Trial Design

1Treatment groups
Experimental Treatment
Group I: HBI-8000 in combination with pembrolizumabExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

HUYABIO International, LLC.Lead Sponsor
11 Previous Clinical Trials
974 Total Patients Enrolled

Media Library

HBI-8000 (Tucidinostat) (Histone Deacetylase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05141357 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: HBI-8000 in combination with pembrolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: HBI-8000 (Tucidinostat) Highlights & Side Effects. Trial Name: NCT05141357 — Phase 2
HBI-8000 (Tucidinostat) (Histone Deacetylase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05141357 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other studies have tested the effects of combining HBI-8000 and pembrolizumab?

"Currently, there are 1010 clinical trials exploring the effects of HBI-8000 in conjunction with pembrolizumab, 127 of which have reached Phase 3. Although many sites for these studies can be found in Sacramento, California, there are 35903 different locations conducting research on HBI-8000 alongside pembrolizumab."

Answered by AI

Is the recruitment stage of this trial still open?

"As of today, the study is still accepting applicants which was first published on March 14th 2022. The most recent update to this trial occurred on October 12th 2022."

Answered by AI

To what extent does the amalgamation of HBI-8000 and pembrolizumab facilitate therapeutic benefits?

"HBI-8000 and pembrolizumab are often used to combat malignant neoplasms. Moreover, this combination has been shown to be efficacious in treating intractable melanoma, microsatellite instability high conditions as well as disease progression after chemotherapy."

Answered by AI

To what extent can HBI-8000 be used in tandem with pembrolizumab without putting individuals at risk?

"According to our team's evaluation, the safety of HBI-8000 combined with pembrolizumab falls on a scale between 1 and 3. This trial is currently in Phase 2, which exhibits some evidence for safety but none pointing towards efficacy; thus it has been assigned a score of 2."

Answered by AI

What is the cap on the total number of individuals enrolled in this trial?

"Affirmative. Information available on clinicaltrials.gov denotes that this research project, which was first posted on March 14th 2022, is actively searching for participants. 24 individuals need to be recruited from 7 distinct medical centres."

Answered by AI

How many medical facilities are presently participating in this trial?

"Currently, 7 medical sites are conducting this trial. These locations include Goodyear, Bakersfield, and Zion as well as an additional 4 centres. To reduce burdensome travel expenses it is suggested that patients choose a clinic close to their residence."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
2022. "A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05141357.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top